ASRs for the Molecular Diagnostic Market

Twenty-one analyte-specific reagents (ASRs) are available for use in molecular diagnostics.

Called MGB (minor groove binders) Eclipse Detection Reagents, the ASRS were launched by Epoch Biosciences, Inc. (Bothell, WA, USA; www.epochbio.com), which states they are the next-generation in DNA probe and primer technology for real-time polymerase chain reaction (PCR), providing an easy-to-use high performance alternative to current chemistries and available as pre-optimized reagents for detecting genetic targets associated with disease.

The 21 reagents include assays for Epstein-Barr virus, Human herpes virus 6, SARS, Factor V Leiden, Angiotensin II, cancer, TNF-alpha, and enterovirus. Epoch sells directly to clinical laboratories in the United States and is pursuing various distribution alternatives in Europe and Japan.

"We have begun to build a base of customers in the clinical laboratory market who desire the level of broad menu, sensitivity, specificity, and reproducibility our technology delivers,” commented William G. Gerber, M.D., CEO of Epoch.




Related Links:
Epoch Biosciences